US Sen. Cassidy On Drug Costs: Exclusivity Based on Innovation, Reference Pricing Proposed
White paper released by Sen. Cassidy, R-La., and upcoming hearing at Senate Health, Education, Labor and Pensions Committee are aimed at building consensus around legislation to lower prices.
You may also be interested in...
The reform 'blueprint' might actually live up to its hype.
Medicare pilot program on value-based purchasing could be challenged by a lack of therapeutic consensus as much as by opposition towards reduced reimbursement.
Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?
A federal appeals court has upheld a lower court's determination that Medicare statutes do not allow the program to limit reimbursement for a drug under Part B to the rate for a "least costly alternative" drug